LYCA
Lycia Therapeutics, Inc.
Price Chart
Latest Quote
$25.05
-1.06 (-4.06%)
Current Price
| Previous Close | $26.11 |
| Open | $26.48 |
| Day High | $26.48 |
| Day Low | $24.03 |
| Volume | 433,120 |
Stock Information
| Shares Outstanding | 52.09M |
| Total Debt | $3.16M |
| Cash Equivalents | $124.32M |
| Revenue | $4.43M |
| Net Income | $-30.03M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.30B |
| EPS (TTM) | $-1.04 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $522.88M |
| Sales | $4.43M |
| Income | $-30.03M |
| Book/sh | $-9.02 |
| Cash/sh | $2.39 |
| Employees | 31 |
Financial Ratios
| Quick Ratio | 12.26 |
| Current Ratio | 12.60 |
| Debt/Eq | 2.18 |
Returns & Margins
| Gross Margin | 291.48% |
| Operating Margin | -762.32% |
Ownership
| Insider Ownership | 7.77% |
| Institutional Ownership | 39.24% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 294.24 |
| P/B | -2.78 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 8.85M |
Performance History
| YTD | -16.50% |
| 10 Years | -16.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-28 | $25.05 | 433,100 |
| 2026-10-27 | $26.11 | 426,800 |
| 2026-10-26 | $28.85 | 965,500 |
| 2026-10-23 | $30.00 | 2,284,000 |
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on LYCA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $6,741,000 | $14,936,000 |
| Operating Revenue | $6,741,000 | $14,936,000 |
| Expenses | ||
| Interest Expense | $31,000 | $39,000 |
| Total Expenses | $46,619,000 | $47,469,000 |
| Other Income Expense | $-1,630,000 | $-117,000 |
| Other Non Operating Income Expenses | $-102,000 | $-117,000 |
| Net Non Operating Interest Income Expense | $4,799,000 | $6,154,000 |
| Interest Expense Non Operating | $31,000 | $39,000 |
| Operating Expense | $46,619,000 | $47,469,000 |
| General And Administrative Expense | $6,112,000 | $6,400,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-36,460,000 | $-26,503,000 |
| Net Interest Income | $4,799,000 | $6,154,000 |
| Interest Income | $4,830,000 | $6,193,000 |
| Normalized Income | $-34,942,696 | $-26,503,000 |
| Net Income From Continuing And Discontinued Operation | $-36,460,000 | $-26,503,000 |
| Total Operating Income As Reported | $-41,406,000 | $-32,533,000 |
| Net Income Common Stockholders | $-36,460,000 | $-26,503,000 |
| Net Income | $-36,460,000 | $-26,503,000 |
| Net Income Including Noncontrolling Interests | $-36,460,000 | $-26,503,000 |
| Net Income Continuous Operations | $-36,460,000 | $-26,503,000 |
| Pretax Income | $-36,709,000 | $-26,496,000 |
| Special Income Charges | $-1,528,000 | $0 |
| Interest Income Non Operating | $4,830,000 | $6,193,000 |
| Operating Income | $-39,878,000 | $-32,533,000 |
| Other | ||
| Tax Effect Of Unusual Items | $-10,696 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-33,960,000 | $-25,281,000 |
| Total Unusual Items | $-1,528,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-1,528,000 | $0 |
| Reconciled Depreciation | $1,190,000 | $1,176,000 |
| EBITDA (Bullshit earnings) | $-35,488,000 | $-25,281,000 |
| EBIT | $-36,678,000 | $-26,457,000 |
| Diluted NI Availto Com Stockholders | $-36,460,000 | $-26,503,000 |
| Tax Provision | $-249,000 | $7,000 |
| Write Off | $120,000 | - |
| Impairment Of Capital Assets | $489,000 | - |
| Restructuring And Mergern Acquisition | $919,000 | $0 |
| Research And Development | $40,507,000 | $41,069,000 |
| Selling General And Administration | $6,112,000 | $6,400,000 |
| Other Gand A | $2,743,000 | $2,912,000 |
| Salaries And Wages | $3,369,000 | $3,488,000 |
Fetched: 2026-10-28
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-113,339,000 | $-77,929,000 |
| Total Assets | $97,215,000 | $150,911,000 |
| Total Non Current Assets | $16,583,000 | $11,083,000 |
| Other Non Current Assets | $161,000 | $183,000 |
| Investmentin Financial Assets | $12,069,000 | $3,007,000 |
| Current Assets | $80,632,000 | $139,828,000 |
| Other Current Assets | $1,510,000 | $1,810,000 |
| Cash Cash Equivalents And Short Term Investments | $79,122,000 | $138,018,000 |
| Cash And Cash Equivalents | $19,268,000 | $30,591,000 |
| Debt | ||
| Total Debt | $2,749,000 | $4,771,000 |
| Long Term Debt And Capital Lease Obligation | $1,727,000 | $2,923,000 |
| Current Debt And Capital Lease Obligation | $1,022,000 | $1,848,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $210,554,000 | $228,840,000 |
| Total Non Current Liabilities Net Minority Interest | $204,068,000 | $205,513,000 |
| Current Liabilities | $6,486,000 | $23,327,000 |
| Other Current Liabilities | $63,000 | $83,000 |
| Current Deferred Liabilities | $0 | $4,741,000 |
| Payables And Accrued Expenses | $3,652,000 | $14,612,000 |
| Payables | $996,000 | $2,270,000 |
| Accounts Payable | $996,000 | $2,270,000 |
| Other Non Current Liabilities | - | $249,000 |
| Equity | ||
| Common Stock Equity | $-113,339,000 | $-77,929,000 |
| Total Equity Gross Minority Interest | $-113,339,000 | $-77,929,000 |
| Stockholders Equity | $-113,339,000 | $-77,929,000 |
| Gains Losses Not Affecting Retained Earnings | $97,000 | $253,000 |
| Other Equity Adjustments | $97,000 | $253,000 |
| Retained Earnings | $-117,560,000 | $-81,100,000 |
| Preferred Securities Outside Stock Equity | $202,341,000 | $202,341,000 |
| Other | ||
| Tangible Book Value | $-113,339,000 | $-77,929,000 |
| Invested Capital | $-113,339,000 | $-77,929,000 |
| Working Capital | $74,146,000 | $116,501,000 |
| Capital Lease Obligations | $2,749,000 | $4,771,000 |
| Total Capitalization | $-113,339,000 | $-77,929,000 |
| Additional Paid In Capital | $4,123,000 | $2,917,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $1,727,000 | $2,923,000 |
| Current Deferred Revenue | $0 | $4,741,000 |
| Current Capital Lease Obligation | $1,022,000 | $1,848,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,749,000 | $2,043,000 |
| Current Accrued Expenses | $2,656,000 | $12,342,000 |
| Investments And Advances | $12,069,000 | $3,007,000 |
| Held To Maturity Securities | $12,069,000 | $3,007,000 |
| Net PPE | $4,353,000 | $7,893,000 |
| Accumulated Depreciation | $-3,616,000 | $-3,184,000 |
| Gross PPE | $7,969,000 | $11,077,000 |
| Other Properties | $7,847,000 | $10,955,000 |
| Machinery Furniture Equipment | $122,000 | $122,000 |
| Other Short Term Investments | $59,854,000 | $107,427,000 |
Fetched: 2026-10-28
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-51,556,000 | $-30,773,000 |
| Operating Activities | ||
| Operating Cash Flow | $-51,362,000 | $-29,502,000 |
| Cash Flow From Continuing Operating Activities | $-51,362,000 | $-29,502,000 |
| Investing Activities | ||
| Capital Expenditure | $-194,000 | $-1,271,000 |
| Investing Cash Flow | $39,964,000 | $-59,710,000 |
| Cash Flow From Continuing Investing Activities | $39,964,000 | $-59,710,000 |
| Financing Activities | ||
| Repurchase Of Capital Stock | $-3,000 | $0 |
| Issuance Of Capital Stock | $0 | $106,600,000 |
| Financing Cash Flow | $77,000 | $106,424,000 |
| Cash Flow From Continuing Financing Activities | $77,000 | $106,424,000 |
| Net Preferred Stock Issuance | $0 | $106,600,000 |
| Preferred Stock Issuance | $0 | $106,600,000 |
| Net Common Stock Issuance | $-3,000 | $0 |
| Net Other Financing Charges | - | $-356,000 |
| Other | ||
| Income Tax Paid Supplemental Data | $1,000 | $86,000 |
| End Cash Position | $19,419,000 | $30,740,000 |
| Beginning Cash Position | $30,740,000 | $13,528,000 |
| Changes In Cash | $-11,321,000 | $17,212,000 |
| Proceeds From Stock Option Exercised | $80,000 | $180,000 |
| Common Stock Payments | $-3,000 | $0 |
| Net Investment Purchase And Sale | $40,123,000 | $-58,439,000 |
| Sale Of Investment | $122,397,000 | $69,075,000 |
| Purchase Of Investment | $-82,274,000 | $-127,514,000 |
| Net PPE Purchase And Sale | $-159,000 | $-1,271,000 |
| Sale Of PPE | $35,000 | $0 |
| Purchase Of PPE | $-194,000 | $-1,271,000 |
| Change In Working Capital | $-17,663,000 | $-3,267,000 |
| Change In Other Working Capital | $-4,741,000 | $-14,936,000 |
| Change In Other Current Liabilities | $-1,917,000 | $-987,000 |
| Change In Payables And Accrued Expense | $-11,210,000 | $13,603,000 |
| Change In Accrued Expense | $-9,980,000 | $12,158,000 |
| Change In Payable | $-1,230,000 | $1,445,000 |
| Change In Account Payable | $-1,230,000 | $1,445,000 |
| Change In Prepaid Assets | $205,000 | $-947,000 |
| Other Non Cash Items | $1,753,000 | $1,207,000 |
| Stock Based Compensation | $1,098,000 | $791,000 |
| Asset Impairment Charge | $489,000 | $0 |
| Amortization Of Securities | $-1,769,000 | $-2,906,000 |
| Depreciation Amortization Depletion | $1,190,000 | $1,176,000 |
| Depreciation And Amortization | $1,190,000 | $1,176,000 |
| Depreciation | $1,190,000 | $1,176,000 |
| Net Income From Continuing Operations | $-36,460,000 | $-26,503,000 |
Fetched: 2026-10-28